OneCell Diagnostics’ Mohan Uttarwar Discusses How AI Helps To Predict Cancer’s Next Move

Company Co-Founder Shares How Decoding Cancer At Single Cell Level Could Take Guesswork Out Of Recurrence With AI-Powered Diagnostics

Part 1 of 2: In an interview with Medtech Insight, Uttarwar breaks down how OneCell’s proprietary single cell biopsy platform is rewriting the rules of cancer diagnostics – not just identifying cancer at the cellular level but predicting its potential return with unprecedented accuracy. He also shares how the company’s approach leverages single cell biopsy technology and machine learning to spot signs of cancer’s return before it manifests clinically.

In an interview with Medtech Insight, Uttarwar breaks down how OneCell’s proprietary single-cell biopsy platform is rewriting the rules of cancer diagnostics
Key Takeaways

· OneCell's platform isolates and analyzes individual circulating tumor cells (CTCs) to provide a more granular and dynamic view of a patient's disease state.

· By training proprietary machine learning models on complex cell-level data, OneCell can assess recurrence risk — offering oncologists a powerful predictive tool for treatment planning.

· With early validation in motion and plans for wider clinical deployment, the company is focused on translating its technology into real-world oncology workflows.

In a world where cancer remains one of the most complex and relentless diseases, OneCell Diagnostics, an artificial intelligence-powered cancer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Interviews

PFA Market Surges As UK NICE Opens Doors And US FDA Approves Boston, J&J Incremental Innovations

 

The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By 

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By 

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.

More from Medtech Insight

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By 

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

European MedTech Keeps Calm Despite US Threats Of 30% Tariffs

 

MedTech Europe wants the EU to continue its commitment to reach a negotiated tariff solution with the US and measured restraint amid escalating trade tensions.

Medtech Will Benefit From Boost To EU’s Quantum Technology Initiative

 

The European Commission is focusing on how tiny particles behave to help create an EU industrial “powerhouse.”